HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

5th Edition of Cardiology World Conference

September 5-7, 2024 | Madrid, Spain

September 05 -07, 2024 | Madrid, Spain
Cardio 2024

Thomas Bernd Dschietzig

Thomas Bernd Dschietzig, Speaker at Cardiovascular Conference
Thomas Bernd Dschietzig
Relaxera GmbH & Co. KG, Germany


Thomas Bernd Dschietzig studied Medicine at Charité, the Medical Faculty of the Humboldt University of Berlin, Germany, and is a specialist of Internal Medicine focused on cardiovascular research. His lab and clinical work has been focused on the study of physiology and pathophysiology of the naturally occurring peptide hormone human relaxin-2. He is Chief Executive Officer and co-founder of Relaxera, a pharma company dedicated to develop synthetic human relaxin-2 for chronic clinical use in cardio-vascular disease, especially in Heart Failure with Preserved Ejection Fraction, HFpEF.